New funding accelerates AI-driven research expansion and brings clinical trials closer to patients everywhere
Columbus, Ohio & New York, 4 December 2025 – Paradigm Health, a fast-growing technology company reshaping the clinical research landscape, has raised an oversubscribed $78 million Series B round. The investment was led by ARCH Venture Partners, with participation from DFJ Growth and existing backers including F-Prime, General Catalyst, GV, Lux Capital, Mubadala Capital, and the American Cancer Society’s BrightEdge Fund. Several investors increased their stakes through super pro-rata commitments.
Paradigm Health is redefining how clinical trials are run by making them faster, smarter, and more accessible to patients across the U.S. and around the world. The new funding will scale the company’s platform to meet rising demand from global biopharmaceutical companies seeking more efficient trials and from health systems wanting to offer research opportunities within their standard care settings.
The company already supports Phase I–III oncology trials for 15 of the world’s top 20 pharmaceutical companies.
ARCH Venture Partners Managing Partner and Paradigm Health Co-Founder Robert Nelsen emphasized the importance of this work, stating that speeding up trials brings lifesaving treatments to patients sooner. He noted that Paradigm Health is building desperately needed infrastructure that allows hospitals and sponsors to run studies more efficiently, at lower cost, and with far better insight.
Following its acquisition of Flatiron Health’s Clinical Research Business, Paradigm Health now operates the largest oncology research network in the U.S. It is also rapidly expanding into neuroscience, cardiovascular medicine, metabolic conditions, and other areas where clinical research is urgently needed.
CEO Kent Thoelke highlighted the disparities in research access across communities. Academic centers typically have the staff and resources to conduct trials, while many community and rural hospitals cannot offer the same opportunities. Paradigm Health aims to close this gap by embedding clinical trials directly into real-world care workflows, reducing the operational burden on providers and giving more patients the chance to participate.
Today, the company’s platform spans 45 U.S. states, 166 healthcare provider organizations, and 2,100 care locations, placing 70% of the U.S. cancer population within reach of a trial site. This network includes 123 community oncology practices and 43 health systems and academic medical centers, with nearly two dozen NCI-Designated Cancer Centers.
Paradigm Health uses AI-driven tools to automate patient matching, streamline site feasibility, and dramatically accelerate enrollment. Health systems using the platform have been able to enroll patients up to four times faster, while reducing administrative strain and shortening development timelines for biopharma companies. The organization has also introduced a Trial Design Service to help sponsors build and run studies within everyday care environments.
DFJ Growth Partner Justin Kao called Paradigm Health an “AI-native platform built for this moment,” noting that clinical trials remain a major bottleneck in delivering new therapies, especially as AI accelerates drug discovery. The combination of advanced technology and a large-scale clinical network positions Paradigm Health as a leader in expanding access to next-generation treatments.
With its expanding national reach, AI-powered infrastructure, and integrated trial design capabilities, Paradigm Health is emerging as a key partner for biopharma companies and health systems committed to making clinical research an accessible part of routine patient care across communities worldwide.
